Ocular Therapeutix, Inc., an integrated biopharmaceutical company committed to redefining the retina experience, will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026 starting at 8:00 AM ET.